record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
JCO integrated efficacy analysis; FDA accelerated approval dossier, 2025
authors
reviewer:will-blair
ONC201 (dordaviprone) demonstrates a 20% objective response rate and 40% disease control rate in pooled analyses of recurrent H3K27M-mutant diffuse midline glioma across five clinical trials (n=50), with median response duration of 11.2 months.
vs_24d093290a28ddd3 · manual_curation
outgoing
vf_b9d6c5c40b15e0c2Pooled trial response rate validated by thalamic location benefit in real-world cohort
vf_0fd7eaae574d9d92H3K27M-selective cytotoxicity mechanistically explains mutation-driven clinical response
vf_82179ae647552ad220% ORR from clinical trials forms regulatory basis for FDA accelerated approval
incoming
No incoming links.
events
vev_f2d98404998f3d20finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_57675c02e6b3b86bfinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.